Objective—Galectin-3 (Gal-3) can affect atherogenesis by multiple mechanisms, but it
remains scarcely known whether plasma Gal-3 levels predict cardiovascular events in …

Abstract Background: Galectin-3 (Gal-3) is implicated in cardiac fibrosis, but its association
with adverse outcomes after myocardial infarction (MI) is unknown. Objectives: The purpose …

Background and aims Galectin-3 binding protein (Gal-3BP) has been associated with
inflammation and cancer, however, its role in coronary artery disease (CAD) and …

Background The relationship between galectin-3 (Gal-3) and coronary artery disease (CAD)
has not been fully elucidated. Aim This study aimed to determine the relationship between …

Abstract Background: Galectin-3 (Gal-3) has been associated with heart failure (HF) and
poor cardiovascular outcomes. However, the effect of longitudinal changes in Gal-3 on …

Objectives: Galectin-3 (Gal-3) is involved in cardiac inflammation and fibrosis, and is in use
as a biomarker that indicates increased risk in heart failure. This study examined the …

Background Galectin‐3 (Gal‐3) participates in different mechanisms involved in
atherothrombosis, such as inflammation, proliferation, or macrophage chemotaxis. Thus …

Aims Recent clinical studies have shown that galectin‐3 is a prognostic indicator in patients
with coronary heart disease and in patients with heart failure. Experimental data suggest that …

In this study, we evaluated the prognostic value of plasma galectin-3 levels in patients with
coronary heart disease (CHD) and chronic heart failure (HF) and selected 261 CHD patients …

Background Inflammatory responses are pivotal in the initiation and development of
premature atherosclerotic lesions. Galectin‐3 represents a valuable biomarker for both …